Dr. Shimon Gross reports

DIAGNOSTEAR SIGNS LETTER OF INTENT TO ADVANCE COMMERCIAL EXPANSION OF TEARX IN INDIA

Diagnostear Technologies Inc. has signed a letter of intent (LOI) with Renovate Biologicals Pvt. Ltd., a Hyderabad-based distribution company active in the ophthalmic market, to support the commercial evaluation and potential distribution of TeaRx in India.

The LOI is part of Diagnostear's global commercialization efforts to expand the company's footprint into one of the world's largest and fastest-growing ophthalmic markets. Under the agreement, Renovate will exclusively lead market-facing activities for TeaRx in India until April 30, 2026, engaging with ophthalmologists, clinics, and key opinion leaders to assess commercial demand and adoption potential.

TeaRx is a CE-IVD-approved, rapid, point-of-care diagnostic test that provides objective assessment of dry eye disease through tear-fluid analysis. Designed for use directly at the point of care, TeaRx addresses a major unmet need in ophthalmology by enabling faster, data-driven clinical decisions without reliance on centralized laboratory testing.

"India is a strategically important market for Diagnostear, with a large patient population and growing demand for efficient, point-of-care diagnostic solutions," said Dr. Shimon Gross, chief executive officer of Diagnostear. "This LOI reflects our continued effort toward building a strong international distribution network and accelerating the commercial rollout of TeaRx globally."

During the LOI period, the parties will work together to define the optimal commercial framework for the Indian market, including pricing structure, distribution strategy and long-term collaboration models, with the objective of progressing toward a definitive commercial agreement by June 1, 2026.

The announcement follows a series of recent milestones for Diagnostear, including international clinical programs and expanding interest in its tear-based diagnostic platform, reinforcing the company's position in point-of-care ocular diagnostics.

About Diagnostear Technologies Inc.

Diagnostear Technologies is a leader in the development of rapid, point-of-care diagnostics for ocular diseases. The company develops multiparametric tests that provide fast, clinically actionable insights based on tear-fluid analysis. Diagnostear's mission is to transform ophthalmic care with accessible diagnostics that support precise, data-driven decision-making.

We seek Safe Harbor.